The reduced availability of NO plays a crucial role in the development of hypertension induced by VEGF inhibitors, while it has been demonstrated that ET-1 enhances NADPH oxidase activity, leading to increased production of ROS and potentially contributing to hypertension by further diminishing the levels of available NO (Kappers et al., 2011; Sarkar et al., 2019). The gene discussed is FMO5; the disease is hypertensive disorder.